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Abstract The immune response involved in each phase of
type 2 diabetes (T2D) development might be different. We
aimed to identify novel inflammatory markers that predict
progression from normoglycemia to pre-diabetes, incident
T2D and insulin therapy. We used plasma levels of 26
inflammatory markers in 971 subjects from the Rotterdam
Study. Among them 17 are novel and 9 previously studied.
Cox regression models were built to perform survival
analysis. Main Outcome Measures: During a follow-up of
up to 14.7 years (between April 1, 1997, and Jan 1, 2012)
139 cases of pre-diabetes, 110 cases of T2D and 26 cases of
insulin initiation were identified. In age and sex adjusted
Cox models, IL13 (HR = 0.78), EN-RAGE (1.30), CFH
(1.24), IL18 (1.22) and CRP (1.32) were associated with
incident pre-diabetes. IL13 (0.62), IL17 (0.75), EN-RAGE
(1.25), complement 3 (1.44), IL18 (1.35), TNFRII (1.27),
IL1ra (1.24) and CRP (1.64) were associated with incident
T2D. In multivariate models, IL13 (0.77), EN-RAGE
(1.23) and CRP (1.26) remained associated with pre-dia-
betes. IL13 (0.67), IL17 (0.76) and CRP (1.32) remained
associated with T2D. IL13 (0.55) was the only marker
associated with initiation of insulin therapy in diabetics.
Various inflammatory markers are associated with pro-
gression from normoglycemia to pre-diabetes (IL13, EN-
RAGE, CRP), T2D (IL13, IL17, CRP) or insulin therapy
start (IL13). Among them, EN-RAGE is a novel inflam-
matory marker for pre-diabetes, IL17 for incident T2D and
IL13 for pre-diabetes, incident T2D and insulin therapy
start.
Keywords Inflammatory markers  Phase-specific  Pre-
diabetes  Type 2 diabetes  Insulin therapy  Novel  IL13 
IL17  EN-RAGE
Introduction
There is increasing evidence that inflammation plays a role
in the development of type 2 diabetes mellitus (DM) [1–3].
In this context, the identification of novel inflammatory
markers associated with the risk of type 2 DM will shed
light on the pathophysiology of the disease and might also
help clinicians to target individuals at highest risk [4, 5]. So
far, a limited number of inflammatory markers have been
investigated. Previous studies reported inflammatory
markers including C-reactive protein (CRP), interleukin 6
(IL6) and adiponectin to associate with the risk of type 2
DM [6–11]. These studies merely investigated inflamma-
tory markers that predict the conversion from normo-
glycemia to type 2 DM.
Healthy individuals are thought to experience a pre-di-
abetes phase before developing type 2 DM. Pre-diabetes is
the presence of blood glucose levels higher than normal,
but not yet high enough to be classified as diabetes [12].
Moreover, type 2 DM could further deteriorate to a stage,
where glucose control is only possible by insulin therapy
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[12, 13]. Progression from normoglycemia to pre-diabetes
is thought to be driven by insulin resistance, while pro-
gression to type 2 DM and need for insulin therapy is
further affected by beta cell dysfunction [14–16]. There-
fore, the immune response involved in each of these phases
might be different [17].
We hypothesized that inflammatory markers are phase-
specific for conversion from normoglycemia to pre-dia-
betes, diabetes and need for insulin therapy. We agnosti-
cally studied the association of a set of inflammatory
markers with progression from normoglycemia to pre-di-
abetes, type 2 DM and finally to insulin therapy.
Materials and methods
Study population
The Rotterdam Study is a prospective population-based
cohort study in Ommoord, a district of Rotterdam, the
Netherlands. The design of the Rotterdam Study has been
described in more detail elsewhere [18]. Briefly, in 1989 all
residents within the well-defined study area aged 55 years
or older were invited to participate of whom 78% (7983 out
of 10,275) agreed. There were no other eligibility criteria to
enter the Rotterdam Study except minimum age and resi-
dency are based on ZIP code. The first examination took
place from 1990 to 1993, after which follow-up examina-
tions were conducted every 3–5 years. This study was
based on data collected during the third visit (1997–1999).
We used data from 971 individuals with available data on
inflammatory markers, drawn as a random control sample
in a case-cohort study of markers for dementia. The Rot-
terdam Study has been approved by the medical ethics
committee according to the Population Screening Act:
Rotterdam Study, executed by the Ministry of Health,
Welfare and Sports of Netherlands. All participants in the
present analysis provided written informed consent to
participate and to obtain information from their treating
physicians.
Measurement of inflammatory markers
Fasting blood samples were collected at the research cen-
tre. Plasma was isolated and immediately put on ice and
stored at -80 C. Citrate plasma (200Ul) was sent in July
2008 to Rules-Based Medicine, Austin, Texas (www.myr
iadrbm.com). The samples were thawed at room tempera-
ture, vortexed, spun at 4000 RPM for 5 min for
clarification and volume was removed for MAP analysis
into a master microtiter plate. Using automated pipetting,
an aliquot of each sample was introduced into one of the
capture microsphere multiplexes of the Multi Analyte
Profile. The mixture of sample and capture microspheres
were thoroughly mixed and incubated at room temperature
for 1 h. Multiplexed cocktails of biotinylated, reporter
antibodies for each multiplex were then added robotically
and after thorough mixing, were incubated for an additional
hour at room temperature. Multiplexes were developed
using an excess of streptavidin–phycoerythrin solution
which was thoroughly mixed into each multiplex and
incubated for 1 h at room temperature. The volume of each
multiplexed reaction was reduced by vacuum filtration and
the volume increased by dilution into matrix buffer for
analysis. Analysis was performed in a Luminex 100
instrument and the resulting data stream was interpreted
using proprietary data analysis software developed at
Rules-Based Medicine (https://myriadrbm.com/scientific-
media/quality-control-systems-white-paper/). For each
multiplex, both calibrators and controls were included on
each microtiter plate. 8-point calibrators were run in the
first and last column of each plate and 3-level controls were
included in duplicate. Testing results were determined first
for the high, medium and low controls for each multiplex
to ensure proper assay performance. Unknown values for
each of the analytes localized in a specific multiplex were
determined using 4 and 5 parameter, weighted and non-
weighted curve fitting algorithms included in the data
analysis package.
Fifty inflammatory markers were quantified using mul-
tiplex immunoassay on a custom designed human multi-
analyte profile. The intra-assay variability was less than 4%
and the inter assay variability was less than 13%. Markers
with more than 60% completeness of measurements were
selected for analysis (26 from 50) [19].
Type 2 diabetes mellitus diagnosis
The participants were followed from the date of baseline
center visit onwards. At baseline and during follow-up,
cases of pre-diabetes and type 2 DM were ascertained
through active follow-up using general practitioners’
records, hospital discharge letters and glucose measure-
ments from Rotterdam Study visits which take place
approximately every 4 years [20]. Diabetes, pre-diabetes
and normoglycemia were defined according to the current
WHO guidelines. Normoglycemia was defined as a fasting
blood glucose level \6.0 mmol/L; pre-diabetes was
defined as a fasting blood glucose between 6.0 and
7.0 mmol/L or a non-fasting blood glucose between 7.7
and 11.1 mmol/L (when fasting samples were unavailable);
type 2 diabetes was defined as a fasting blood glucose
C7.0 mmol/L, a non-fasting blood glucose C11.1 mmol/L
(when fasting samples were unavailable), or the use of
blood glucose lowering medication [20]. Information
regarding the use of blood glucose lowering medication
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was derived from both structured home interviews and
linkage to pharmacy dispensing records. At baseline, more
than 95% of the Rotterdam Study population was covered
by the pharmacies in the study area. All potential events of
pre-diabetes and type 2 diabetes were independently
adjudicated by two study physicians. In case of disagree-
ment, consensus was sought with an endocrinologist. Fol-
low-up data was complete until January 1st 2012,
calculated as a separate variable for every outcome, taking
in account the hierarchy of events as follows: pre-diabetes,
type 2 diabetes, insulin therapy start [20].
Covariates
Height and weight were measured with the participants
standing without shoes and heavy outer garments. Body
mass index (BMI) was calculated as weight divided by
height squared (kg/m2). Waist circumference was mea-
sured at the level midway between the lower rib margin
and the iliac crest with participants in standing position
without heavy outer garments and with emptied pockets,
breathing out gently. Blood pressure was measured at the
right brachial artery with a random-zero sphygmo-
manometer with the participant in sitting position, and the
mean of 2 consecutive measurements was used. Informa-
tion on medication use, medical history and smoking
behaviour was collected via computerized questionnaires
during home visits. Smoking was classified as current
versus non-current smokers. Participants were asked whe-
ther they were currently smoking cigarettes, cigars, or
pipes. History of cardiovascular disease was defined as a
history of coronary heart diseases (myocardial infarction,
revascularization, coronary artery bypass graft surgery or
percutaneous coronary intervention) and was verified from
the medical records of the general practitioner. Alcohol
intake was assessed in grams of ethanol per day. Insulin,
glucose, total cholesterol (TC), high-density lipoprotein
cholesterol (HDL-C), triglycerides (TG) were measured on
the COBAS 8000 Modular Analyzer (Roche Diagnostics
GmbH). The corresponding interassay coefficients of
variations are the following: insulin\8%, glucose\1.4%,
lipids\2.1%. HOMA-IR (the homeostatic model assess-
ment to quantify insulin resistance) was calculated divid-
ing the product of fasting glucose (in mmol/L) and fasting
insulin (in mU/L) by 22.5. HOMA-B (the homeostatic
model assessment of b-cell function) was calculated
dividing the product of fasting insulin (in mU/L) and 20 by
the difference of glucose (in mmol/L) with 3.5 [21].
Statistical analyses
We used linear regression to investigate the association
between each inflammatory marker and fasting glucose and
fasting insulin in 851 subjects free of diabetes at baseline
(excluding 120 prevalent diabetes cases from 971 subjects
with available data) as presented at Figs. 1, 2, Supple-
mentary Table 2.1, Supplementary Table 2.2. Also the
associations between markers with HOMA-IR and HOMA-
B were investigated using linear regression (Supplementary
Table 3). Markers with a right-skewed distribution were
transformed to the natural logarithmic scale (including
fasting glucose and insulin). For a better comparison
between the inflammatory markers, all markers were
standardized by dividing the measured value by the stan-
dard deviation. We defined marker values as an outlier
when the value was[4 standard deviations higher or lower
than the mean of the normal variable (not natural log
transformed). Participants were excluded from the analyses
when the marker value for this person was an outlier. A
multiple imputation procedure was used for missing
covariates (N = 5 imputations). The analyses with incident
pre-diabetes, incident type 2 DM and need for insulin
therapy were performed using Cox proportional hazard
models to calculate hazard ratios (HRs) and 95% confi-
dence intervals (CI). The first model with incident pre-
diabetes and diabetes was adjusted for age and sex
(Table 2). Significant markers were further investigated in
multivariable models (Table 3). In the second model, we
additionally adjusted for body mass index, waist circum-
ference, total cholesterol, HDL-cholesterol, medication for
hypertension, smoking, prevalent cardiovascular disease
and lipid lowering medication. In the third model we
additionally adjusted for C-reaction protein (CRP) levels
(except for CRP marker). We sought to investigate the
associations between the inflammatory markers and the
need for insulin therapy in 115 prevalent diabetes cases
with no prevalent use of insulin at baseline (from 120
prevalent cases in total). The inflammatory markers were
not correlated to each other, representing 26 independent
variables. As a sensitivity analysis, to identify the most
robust findings in every analysis, we applied a Bonferroni
corrected p value of 1.9 9 10-3 (0.05/26 markers).The
analyses were performed using IBM SPSS Statistics for
Windows (IBM SPSS Statistics for Windows, Armonk,
New York: IBM Corp) and R V.3.0.1 (R Foundation for
Statistical Computing, Vienna, Austria).
Results
Table 1 summarizes the baseline characteristics of 971
participants, including 120 prevalent diabetes cases. The
mean (SD) age at baseline was 73.0 (7.5) years and 44.8%
of our population sample were males. The mean BMI (SD)
was 26.7 (3.9) kg/m2 and 12.6% of the study population
used statin.
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Fig. 1 Associations of inflammatory markers with fasting glucose.
CD40, cluster of differentiation 40; CD40 ligand, cluster of differ-
entiation 40 ligand; EN-RAGE, Extracellular Newly identified
Receptor for Advanced Glycation End-products binding protein;
FAS, Fas Cell Surface Death Receptor; HCC4, Human CC
chemokine-4; IL13, interleukin 13; IL16, interleukin 16; IL17,
interleukin 17; IL8, interleukin 8; MDC, Monocyte Derived
Chemokine; MIP1alpha, Macrophage Inflammatory Protein 1 alpha;
MIP1beta, Macrophage Inflammatory Protein 1 beta; PARC, Pul-
monary and Activation-Regulated Chemokine; sRage, Soluble
Receptor of Advanced Glycation End-products; TRAILR3, Tumor
Necrosis Factor-related Apoptosis-inducing Ligand Receptor 3; CFH,
Complement Factor H; IL18, interleukin 18; MCP1, Monocyte
Chemotactic Protein 1; RANTES, Regulated Upon Activation,
Normally T-Expressed, And Presumably Secreted; TNFR-II, Tumor
Necrosis Factor Receptor 2; IL1ra, Interleukin 1 Receptor Antagonist;
CRP, C-Reactive Protein. *Significant associations between the
marker and fasting glucose. Adjusted for age, sex, BMI, waist
circumference (WC), Total Cholesterol, HDL, medication for hyper-
tension, smoking, prevalent CVD, lipid lowering medication
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Fig. 2 Associations of inflammatory markers with fasting insulin.
CD40, cluster of differentiation 40; CD40 ligand, cluster of differ-
entiation 40 ligand; EN-RAGE, Extracellular Newly identified
Receptor for Advanced Glycation End-products binding protein;
FAS, Fas Cell Surface Death Receptor; HCC4, Human CC
chemokine-4; IL13, interleukin 13; IL16, interleukin 16; IL17,
interleukin 17; IL8, interleukin 8; MDC, Monocyte Derived
Chemokine; MIP1alpha, Macrophage Inflammatory Protein 1 alpha;
MIP1beta, Macrophage Inflammatory Protein 1 beta; PARC, Pul-
monary and Activation-Regulated Chemokine; sRage, Soluble
Receptor of Advanced Glycation End-products; TRAILR3, Tumor
Necrosis Factor-related Apoptosis-inducing Ligand Receptor 3; CFH,
Complement Factor H; IL18, interleukin 18; MCP1, Monocyte
Chemotactic Protein 1; RANTES, Regulated Upon Activation,
Normally T-Expressed, And Presumably Secreted; TNFR-II, Tumor
Necrosis Factor Receptor 2; IL1ra, Interleukin 1 Receptor Antagonist;
CRP, C-Reactive Protein. *Significant associations between the
marker and fasting insulin. Adjusted for age, sex, BMI, waist
circumference (WC), Total Cholesterol, HDL, medication for hyper-
tension, smoking, prevalent CVD, lipid lowering medication
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Baseline levels of inflammation markers are presented in
Supplementary Table 1.4.
Cross-sectional analysis
Figures 1 and 2 present the multivariable adjusted associ-
ations between the inflammatory markers and fasting glu-
cose, fasting insulin in 851 subjects free of diabetes at
baseline. Three markers, EN-RAGE, IL13 and sRAGE
were significantly associated with fasting glucose. CD40,
EN-RAGE, FAS, HCC4, IL13, IL18, TRAILR3, CFH,
complement 3, IL18 and IL1ra were significantly associ-
ated with fasting insulin.
Prospective analyses
During a median follow-up of 9.5 years in 698 subjects
free of pre-diabetes at baseline, 139 cases of pre-diabetes
were identified (21 pre-diabetes cases per 1000 person-
years). Supplementary Table 1.1 presents baseline charac-
teristics among pre-diabetes cases and non-cases.
In age and sex adjusted model, EN-RAGE, IL13, CFH,
IL18 and CRP were associated with incident pre-diabetes
(Table 2). In multivariate models, IL13 (HR = 0.77), EN-
RAGE (HR = 1.23) and CRP (HR = 1.26) remained
associated with incident pre-diabetes (Table 3).
During a median follow-up of 12.1 years in 851 subjects
free of diabetes at baseline, 110 cases of incident type 2
diabetes were identified (11 diabetes cases per 1000 per-
son-years). Supplementary Table 1.2 presents baseline
characteristics among diabetes cases and non-cases.
In age and sex adjusted model, EN-RAGE, IL13, IL17,
complement 3, IL18, TNFRII, IL1ra and CRP were asso-
ciated with incident type 2 diabetes (Table 2).
In multivariate models, IL13 (HR = 0.67), IL17
(HR = 0.76) and CRP (HR = 1.32) remained associated
with incident type 2 diabetes (Table 3).
During a median follow-up of 7.5 years in 115 prevalent
diabetics free of insulin at baseline, 26 started insulin
therapy (30 insulin starters per 1000 person-years). Sup-
plementary Table 1.3 presents baseline characteristics
among insulin starters and non-starters.
The only marker associated with need for insulin ther-
apy was IL13. In age and sex adjusted model, the risk for
insulin therapy start was 45% lower per standard deviation
increase in the natural log-transformed IL13 (HR = 0.55,
95% CI: 0.34, 0.90), (Supplementary Table 4). The asso-
ciation between 1L13 and initiation of insulin therapy
remained significant after further adjustment for BMI,
waist circumference, total cholesterol, HDL, medication
for hypertension, smoking, prevalent CVD, lipid lowering
medication (HR = 0.49, 95% CI: 0.28, 0.91).
Discussion
Although a sizable number of studies have documented the
association of inflammatory markers with type 2 DM, most
of them investigated the risk to become diabetic, but not
the risk of pre-diabetes and insulin therapy start [8]. In this
study we investigated a wide range of inflammatory
markers for phase-specific prediction of progression to type
2 DM and identified EN-RAGE, IL13 and IL17 as novel
inflammatory markers. Higher EN-RAGE levels were
associated with an increased risk of incident pre-diabetes,
whereas higher IL13 levels were associated with a
decreased risk of pre-diabetes, incident type 2 DM and
need for insulin therapy. Higher IL17 levels were associ-
ated with a decreased risk of incident type 2 DM. In
addition, this study reconfirm the previously found asso-
ciations between high CRP levels and the increased risk for
type 2 diabetes [6–8].
EN-RAGE, also known as S100A12 or Calgranulin C, is
a calcium-binding pro inflammatory protein mainly secre-
ted by granulocytes. The best known target protein of EN-
RAGE are RAGE (Receptor for Advanced Glycation
Endproducts) [22] and TLR4 (Toll-like receptor 4) [23].
Ligation of EN-RAGE with RAGE or TLR4, which are
both gatekeepers of the innate immune system, activates
inflammatory cascades, including the NF-jB pathway and
JNK (c-Jun NH2–terminal kinase) [24]. NF-jB and JNK
Table 1 Baseline characteristics of study participants
Characteristic Valuea
Total population number 971
Age (years) 73.0 ± 7.5
Men, n (%) 435.0 (44.8)
Waist circumference (m) 0.9 ± 0.1
Body mass index (kg/m2) 26.7 ± 3.9
Systolic blood pressure (mmHg) 144.0 ± 21.7
Diastolic blood pressure (mmHg) 75.0 ± 11.0
Hypertension medication with indication, n (%) 744.0 (76.6)
Total cholesterol (mmol/L) 5.8 ± 1.0
HDL cholesterol (mmol/L) 1.4 ± 0.4
Fasting glucose (mmol/L) 5.6 (3.54)
Fasting insulin (uIU/L) 9.4 (19.87)
Current smokers, n (%) 137.0 (14.1)
Former smokers, n (%) 483.0 (49.7)
Prevalent CVD, n (%) 201.0 (20.7)
Alcohol intake in drinkers (76%) (g/day) 5.71 (42.73)
Lipid lowering medication, n (%) 122.0 (12.6)
HDL, high density lipoproteins; CVD, cardiovascular disease
a Plus-minus values are mean ± standard deviation or median (inter-
quartile range)
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are both signaling pathways involved in the pathogenesis
of insulin resistance and type 2 DM [25]. EN-RAGE is
positively associated with chronic inflammatory disorders
such as inflammatory bowel disease, chronic kidney dis-
ease, subclinical atherosclerosis and coronary artery dis-
ease. A cross-sectional study in Italian population found
that prediabetic patients exhibited lower RAGE plasma
levels as well as increased levels of proinflammatory
S100A12 in both prediabetic and diabetic patients [26]. In
addition, we have previously reported the positive
association between EN-RAGE and incident CHD in the
Rotterdam Study [19]. Kosaki et al. [27] observed
increased plasma EN-RAGE levels in patients with type 2
DM. EN-RAGE was significantly associated with both
HOMA-IR and HOMA-B, suggesting proinflammatory
EN-RAGE leads to incident type 2 DM via inflammation-
induced insulin resistance as well as via B-cell dysfunction
(Supplementary Table 3).
Interleukin 13 (IL13) is a cytokine mainly produced by
the T-helper (Th)-2 subset of lymphocytes, but also from
Table 2 Age and sex-adjusted
associations between markers
and incident pre-diabetes,
incident type 2 diabetes mellitus
Marker Incident pre-diabetes Incident diabetes
HR (95% CI) P value HR (95% CI) P value
CD40 (ng/mL) 0.93 (0.72, 1.19) 0.5 1.18 (0.91, 1.52) 0.2
CD40 liganda (ng/mL) 0.95 (0.79, 1.16) 0.6 1.06 (0.85, 1.32) 0.6
EN-RAGEa (ng/mL) 1.30 (1.08, 1.56) 5.0 9 1023 1.25 (1.01, 1.54) 4.0 9 1022
Eotaxina (pg/mL) 0.95 (0.79, 1.15) 0.6 0.98 (0.80, 1.21) 0.8
FASa (ng/mL) 1.09 (0.88, 1.35) 0.4 1.09 (0.87, 1.38) 0.4
HCC4 (ng/mL) 1.11 (0.90, 1.35) 0.3 1.24 (0.99, 1.53) 5.4 3 10-2
IL13a (pg/mL) 0.78 (0.64, 0.94) 8.0 9 1023 0.62 (0.50, 0.76) b5.0 9 1026
IL16 (pg/mL) 1.07 (0.88, 1.29) 0.4 1.17 (0.94, 1.45) 0.1
IL17a (pg/mL) 0.97 (0.81, 1.16) 0.7 0.75 (0.62, 0.91) 3.0 9 1023
IL8a (pg/mL) 1.05 (0.87, 1.27) 0.5 1.19 (0.97, 1.47) 0.1
MDC (pg/mL) 0.94 (0.75, 1.17) 0.5 1.19 (0.94, 1.50) 0.1
MIP1 alphaa (pg/mL) 1.09 (0.90, 1.32) 0.3 1.08 (0.87, 1.34) 0.5
MIP1 betaa (pg/mL) 1.05 (0.87, 1.26) 0.6 1.00 (0.81, 1.25) 0.9
PARC (ng/mL) 1.08 (0.88, 1.32) 0.4 0.94 (0.75, 1.19) 0.6
sRAGEa (ng/mL) 0.95 (0.79, 1.14) 0.6 0.91 (0.75, 1.11) 0.3
TRAILR3a (ng/mL) 1.18 (0.98, 1.41) 8.1 3 10-2 1.19 (0.97, 1.47) 9.1 3 10-2
CFHa (ug/mL) 1.24 (1.02, 1.49) 2.8 3 1022 1.05 (0.87, 1.28) 0.6
Complement 3a (mg/mL) 1.13 (0.94, 1.36) 0.1 1.44 (1.17, 1.77) b1.0 9 1023
IL18a (pg/mL) 1.22 (1.02, 1.47) 3.2 9 1022 1.35 (1.10, 1.65) 4.0 9 1023
MCP1a (pg/mL) 0.93 (0.76, 1.14) 0.4 0.99 (0.79, 1.25) 0.9
MIFa (ng/mL) 0.97 (0.82, 1.14) 0.6 1.11 (0.92, 1.35) 0.2
RANTESa (ng/mL) 0.89 (0.75, 1.05) 0.1 1.05 (0.87, 1.27) 0.6
Resistina (ng/mL) 1.02 (0.85, 1.24) 0.8 0.96 (0.78, 1.18) 0.7
TNFRIIa (ng/mL) 0.97 (0.79, 1.18) 0.7 1.27 (1.03, 1.58) 2.9 9 1022
Il1raa (pg/mL) 1.04 (0.87, 1.25) 0.6 1.24 (1.02, 1.51) 3.4 9 1022
CRPa (ug/mL) 1.32 (1.10, 1.58) 3.0 9 1023 1.64 (1.33, 2.02) b4.0 9 1026
CD40, cluster of differentiation 40; CD40 ligand, cluster of differentiation 40 ligand; EN-RAGE, Extra-
cellular Newly identified Receptor for Advanced Glycation End-products binding protein; FAS, Fas Cell
Surface Death Receptor; HCC4, Human CC chemokine-4; IL13, interleukin 13; IL16, interleukin 16; IL17,
interleukin 17; IL8, interleukin 8; MDC, Monocyte Derived Chemokine; MIP1alpha, Macrophage
Inflammatory Protein 1 alpha; MIP1beta, Macrophage Inflammatory Protein 1 beta; PARC, Pulmonary and
Activation-Regulated Chemokine; sRage, Soluble Receptor of Advanced Glycation End-products;
TRAILR3, Tumor Necrosis Factor-related Apoptosis-inducing Ligand Receptor 3; CFH, Complement
Factor H; IL18, interleukin 18; MCP1, Monocyte Chemotactic Protein 1; RANTES, Regulated Upon
Activation, Normally T-Expressed, And Presumably Secreted; TNFR-II, Tumor Necrosis Factor Receptor
2; IL1ra, Interleukin 1 Receptor Antagonist; CRP, C-Reactive Protein
Bold values indicate the significance level of P B 0.05
a Naturally log-transformed
b Sensitivity analysis: significant after Bonferroni correction (p = 0.05/26 = 1.9 9 10-3)
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non-T-cell populations such as mast cells, basophils, den-
dritic cells, keratinocytes and eosinophils [28–30]. IL13 is
a regulator of inflammation and immune responses [31].
IL13 has a common receptor unit (a-chain) with interleukin
4 (IL4), which explains the similarities between IL13 and
IL4 [32]. Previous research has reported a preventive effect
of IL4 on the onset of diabetes in non-obese diabetic mice
(NOD mice) [33]. Furthermore, Zaccone et al. [34] found
that IL13 prevents autoimmune diabetes in NOD mice,
providing evidence that IL13 down-regulates the immune-
inflammatory diabetogenic pathways, which is in agree-
ment with our findings. Wong et al. [35] suggested the
stimulation of IL13 receptors on T-cells, as a new pathway
for tolerance induction in NOD mice. In addition, IL13 is a
Table 3 Multivariable-adjusted
associations between markers
and incident pre-diabetes,
incident type 2 diabetes mellitus
Marker Incident pre-diabetes Incident type 2 diabetes
HR (95%CI) P-value HR (95%CI) P-value
IL13
Model 1 0.78 (0.64, 0.94) 8.0 3 1023 0.62 (0.50, 0.76) 5.0 3 1026
Model 2 0.78 (0.63, 0.98) 2.9 3 1022 0.68 (0.53, 0.88) 4.0 3 1023
Model 3 0.77 (0.62, 0.96) 2.2 3 1022 0.67 (0.52, 0.86) 2.0 3 1023
IL17
Model 1 0.97 (0.81, 1.16) 0.7 0.75 (0.62, 0.91) 3.0 3 1023
Model 2 0.97 (0.82, 1.16) 0.7 0.75 (0.62, 0.91) 4.0 3 1023
Model 3 0.98 (0.82, 1.17) 0.8 0.76 (0.63, 0.93) 7.0 3 1023
EN-RAGE
Model 1 1.30 (1.08, 1.56) 5.0 3 1023 1.25 (1.01, 1.54) 4.0 3 1022
Model 2 1.28 (1.06, 1.56) 1.2 3 1022 1.13 (0.89, 1.41) 0.3
Model 3 1.23 (1.01, 1.51) 4.1 3 1022 1.05 (0.83, 1.32) 0.6
Complement 3
Model 1 1.13 (0.94, 1.36) 0.1 1.44 (1.17, 1.77) 1.0 3 1023
Model 2 1.05 (0.86, 1.27) 0.6 1.19 (0.96, 1.49) 0.1
Model 3 0.99 (0.82, 1.21) 0.9 1.10 (0.87, 1.39) 0.4
CFH
Model 1 1.24 (1.02, 1.49) 2.8 3 1022 1.05 (0.87, 1.28) 0.6
Model 2 1.19 (0.99, 1.45) 6.5 3 10-2 0.98 (0.81, 1.18) 0.8
Model 3 1.18 (0.97, 1.42) 9.7 3 10-2 0.98 (0.81, 1.18) 0.8
IL18
Model 1 1.22 (1.02, 1.47) 3.2 3 1022 1.35 (1.10, 1.65) 4.0 3 1023
Model 2 1.17 (0.97, 1.41) 0.1 1.22 (0.98, 1.50) 6.7 3 10-2
Model 3 1.13 (0.94, 1.36) 0.1 1.18 (0.96, 1.46) 0.1
TNFRII
Model 1 0.97 (0.79, 1.18) 0.7 1.27 (1.03, 1.58) 2.9 3 1022
Model 2 0.89 (0.73, 1.09) 0.2 1.08 (0.86, 1.37) 0.5
Model 3 0.81 (0.66, 1.01) 6.1 3 10-2 0.99 (0.78, 1.28) 0.9
IL1ra
Model 1 1.04 (0.87, 1.25) 0.6 1.24 (1.02, 1.51) 3.4 3 1022
Model 2 0.97 (0.80, 1.17) 0.7 1.03 (0.83, 1.27) 0.8
Model 3 0.94 (0.78, 1.14) 0.5 0.98 (0.79, 1.22) 0.8
CRP
Model 1 1.32 (1.10, 1.58) 3.0 3 1023 1.64 (1.33, 2.02) 4.0 3 1026
Model 2 1.26 (1.04, 1.53) 1.8 3 1022 1.32 (1.05, 1.67) 1.7 3 1022
Model 3 NA NA NA NA
Bold values indicate the significance level of P B 0.05
(1) Age and sex adjusted
(2) Additionally adjusted for BMI, waist circumference (WC), Total Cholesterol, HDL, medication for
hypertension, smoking, prevalent CVD, lipid lowering medication
(3) Additionally adjusted for CRP
Novel inflammatory markers for incident pre-diabetes and type 2 diabetes: the Rotterdam Study 223
123
B cell stimulating factor, which further supports our
observation [36]. Stanya et al. [37] conclude that IL13
mitigates proinflammatory response in mice and regulates
glucose homeostasis via the IL-13ra1–STAT3 signaling
pathway in the liver, and that this pathway might provide a
target for glycemic control in type 2 DM.
We also investigated the associations of IL13 with
HOMA-IR and HOMA-B. IL13 was associated with both
of them, suggesting a protective role against insulin resis-
tance and B-cell dysfunction (Supplementary Table 3).
There are six members in the interleukin 17 (IL17)
cytokine family, including IL17A, IL17B, IL17C, IL17D,
IL17E (also known as IL25) and IL17F. Among all the
members, the biological function and regulation of IL17A
and IL17F are best understood. IL17A was produced
mainly in T cells, whereas IL-17F was produced in T cells,
innate immune cells, and epithelial cells. Functionally,
both IL17A and IL17F mediate pro-inflammatory respon-
ses [38, 39]. IL17 family cytokines have been linked to
many autoimmune diseases, including multiple sclerosis,
rheumatoid arthritis, inflammatory bowel disease and
psoriasis [40]. The role of IL17 on the risk for type 2 DM
remains unclear. Roohi A et al. [41] reported no associa-
tion between serum IL17 levels and type 1 and 2 diabetes.
Another study found that therapeutic improvement of
glucoregulation in newly diagnosed type 2 DM patients is
associated with a reduction of IL-17 levels [42]. Our study
suggest a protective IL17 cytokine against the risk for type
2 DM (HR = 0.76), which is controversial and novel to the
already known pro-inflammatory role of IL17 family
cytokines. However, a cross-sectional case–control study
has reported inverse associations of serum levels of IL17
with type 2 DM as well as with retinopathy, which is in line
with our findings [43].
This study has certain strengths and limitations. To our
knowledge, this is the first prospective population-based
cohort study to investigate the association between a large set
of novel inflammatory markers and the progression of type 2
DM with long-term follow-up. Furthermore, we performed
sensitivity analysis, adjusting the type I error for multiple
testing in order to highlight the most robust associations in
every analyses. However, given the novelty of the markers,
we reported significant findings at the level of 0.05 to avoid
missing possibly important findings [44]. Beyond the iden-
tification of new novel inflammatory markers for type 2
diabetes, our findings relate them specifically to different
stages of the disease. We are also aware of some limitations
of the study. First, we had to exclude inflammatory markers
with very low serum concentrations. However, the selected
markers have[60% completeness of measurements, indi-
cating acceptable quality of quantification. Second, our
population is 55 years and older, thus generalization of the
results to a younger age should be done with caution. Also,
the Rotterdam Study mainly includes individuals from
European Ancestry (98%). The effect estimates might differ
between ethnicities.
A better prevention of type 2 DM requires the targeting
of subjects at high risk in very early phases, such as pre-
diabetes [12]. In this context, it is worth to investigate
novel inflammatory markers that might be detectors of
different stages of type 2 DM development [17].
In conclusion, our results show various inflammatory
markers are associated with the progression from normo-
glycemia to type 2 DM and need for insulin therapy in a
phase-specific manner. Among them, EN-RAGE is a novel
inflammatory marker for pre-diabetes, IL17 for incident
type 2 DM and IL13 for pre-diabetes, incident type 2 DM
and insulin therapy start. This study only indicates new
associations, emphasizing the need for further studies to
establish the role of EN-RAGE, IL13 and IL17 in the
development of type 2 diabetes.
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